杨宁介入医学网

Studies on HAIC have included populations with various degrees of intrahepatic tumor burden, including the possible presence of PVT/EHS. 对HAIC的研究包括了不同程度肝内肿瘤负荷的人群，包括可能存在PVT/EHS。 Studies on patients with PVT who r...

Immune checkpoint inhibitorbased combinations have changed the treatment paradigm for advanced HCC [59,60] and are likely to remain the cornerstone of systemic treatment in the next few years. 基于免疫检查点抑制剂的联合治疗已经改变了晚期HC...

HAIC combined with radiation therapy (RT) has also been extensively investigated, particularly in subgroups of patients with PVT. HAIC联合放疗(RT)也已被广泛研究，特别是在PVT患者的亚组中。 Han et al. [ 51 ] conducted a small-scale single-ar...

HAIC has been combined with sorafenib to leverage the synergistic effects of the combination. HAIC已与索拉非尼联合使用，以利用该联合使用的协同效应。 A randomized Phase 2 trial was conducted to compare HAIC plus sorafenib with sorafenib alo...

Subcutaneous or intramuscular interferon-alpha (IFN-) has been used in combination with intravenous chemotherapy for advanced HCC to enhance antitumor activity [55]. 皮下或肌内干扰素(IFN-)已与静脉化疗联合用于晚期HCC，以增强抗肿瘤活性[ 55 ]...

肝癌是全世界范围内常见的消化系统恶性肿瘤，我国肝癌的发病率和死亡率在恶性肿瘤中分别排列第4位和第2位。肝癌具有早诊困难、进展迅速，预后较差等特征， 特别是对于中晚期肝癌患者的治疗选择非常有限。 一项2期临床试验评估了钇90微球疗法联合免疫药物Opdiv...

超声显示高回声区域替代原先的病变。但是这一特征并不可靠。 The US shows hyperechoic area replacing the original lesion. This feature, however is unreliable for assessing the outcome of treatment....

Trial design: EPOCH-2 Study【1】 Chemotherapy (physician choice) =FOLFOX4, CAPOX, FOLFIRI (1st line for mets) EPOC Resectable Liver Mets Chemo +/- Cetuximab 有或没有西妥昔单抗的化疗结果 Addition of cetuximab to chemotherapy and surgery for...

名词和定义：Neoadjuvant chemotherapy by hepatic infusion for given to resectable liver metastases to facilitate surgery 经导管新辅助化疗（neoadjuvant or primary chemotherapy by hepatic arterial infusion）是指在肝转移病变局部实施手术之前，...

是指结直肠癌肝转移病灶一期切除术后经导管肝动脉化疗以改善手术结果。 从伦理学角度，临床试验必须是肝动脉化疗+全身化疗 vs. 全身化疗的比较。 研究一 MSKCC：肝动脉灌注+全身化疗 vs. 全身化疗。终点目标：增加两年生存期。 Kemeny NE Updated Hepatic Pr...